Abstract: The active form of vitamin D (1a,25-dihydroxyvitamin D) acts as a steroid hormone and binds to the vitamin D receptor. This receptor is expressed in most cell types including cells in the central nervous system (CNS). Vitamin D has several functions in the body including effects on brain development, neuroprotection and immunological regulation. It has been shown that vitamin D has antiproliferative activities in different cancer cell lines. Tacalcitol and calcipotriol are synthetic analogues of 1a,25-dihydroxyvitamin D with reduced effect on calcium metabolism. The aim of this study was to analyse the effects of tacalcitol and calcipotriol on cell viability, proliferation and migration in the human glioblastoma cell line T98G. Glioblastoma is the most lethal type of primary tumours in the CNS. Both analogues decreased cell viability and/or growth, dose-dependently, in concentrations between 1 nM and 10 lM. Manual counting indicated suppressive effects by the vitamin D analogues on proliferation. Treatment with tacalcitol strongly suppressed thymidine incorporation, indicating that the vitamin D analogues mainly inhibit proliferation. Also, effects on cell migration were measured with wound-healing assay. Both calcipotriol and tacalcitol reduced the migration rate of T98G cells compared to vehicle-treated cells. However, they had no effect on caspase-3 and -7 activities, suggesting that their mechanism of action does not involve induction of apoptosis. The current results indicate that the vitamin D analogues tacalcitol and calcipotriol strongly reduce proliferation and migration of human glioblastoma T98G cells, suggesting a potential role for this type of compounds in treatment of brain cancer.
Glioblastoma multiforme (GBM) is the most common malignant and lethal primary brain tumour of the central nervous system (CNS), with a median survival of 10-15 months and with a 5-year survival rate of 5% [1, 2] . The current standard treatment includes surgery followed by radiation and chemotherapy [3] . Glioblastoma is a difficult cancer to treat, and there is currently no cure for GBM, which is highly invasive and grows rapidly. New alternative treatments are therefore warranted.
The active form of vitamin D (1a,25-dihydroxyvitamin D) acts as a steroid hormone and binds to the vitamin D receptor (VDR) [4] . This receptor is expressed in most cells and tissues, including neuronal and glial cells in the CNS. There is an association between VDR expression and patient prognosis in various tumour types [5] [6] [7] . There are also several studies indicating that vitamin D deficiency is associated with an increased risk of developing cancer and other illnesses [8] . The classical function of vitamin D is to regulate calcium and phosphate homoeostasis, which is important for bone formation and resorption. Vitamin D has the ability to affect gene expression in most cell types. It has also been shown that vitamin D has effects on cell proliferation and differentiation, and influences the immune system, hormone regulation and the cardiovascular system [9] [10] [11] . In vitro studies have shown that 1a,25-dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ) inhibits cell proliferation and induces apoptosis in several tumour cell lines, including breast, prostate, osteosarcoma, colon and ovarian cancer cell lines [12] [13] [14] . In vivo studies with rodents have shown that vitamin D significantly reduces the incidence of colonic tumours, has antineoplastic effects on breast tumours and delays the progression of ovarian cancer [14] [15] [16] . These findings suggest that vitamin D has potential applications in cancer prevention and treatment. However, the hyperphysiological doses necessary for antitumour activity of 1a,25 (OH) 2 D 3 can cause the side effect of hypercalcaemia and may therefore cause problems in treatment of cancer [17] . For this reason, the synthesis of analogues with reduced effects on calcium metabolism has been initiated. Tacalcitol and calcipotriol are two synthetic 1a,25(OH) 2 D 3 analogues with less hypercalcaemic activities than that of 1a,25(OH) 2 D 3 [18, 19] . However, although these have shown promise in some other cell types, very little is known about the effects of vitamin D analogues on human glioblastoma cells [20] . This study analyses the effects of 1a,25(OH) 2 D 3 , tacalcitol and calcipotriol on cell viability, proliferation and migration in the human glioblastoma cell line T98G. This cell line was selected for its known ability to express VDR [20, 21] . Despite the presence of VDR in tumours from patients, many glioblastoma cell lines are unable to respond to vitamin D, most likely due to the absence of this receptor [22, 23] . The data provide evidence that the vitamin D analogues tacalcitol and calcipotriol strongly reduce proliferation and migration of human glioblastoma T98G cells, suggesting a potential role for vitamin D analogues in treatment of brain tumours.
Materials and Methods
Materials. The human glioblastoma cell line T98G (ATCC CRL-1690) was obtained from the American Type Culture Collection (Manassas, VA, USA). Materials for cell culturing were obtained from Author for correspondence: Maria Norlin, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, S-751 24 Uppsala, Sweden (e-mail: maria.norlin@farmbio.uu.se).
Gibco. MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) was purchased from Sigma (Stockholm, Sweden). 1a,25 (OH) 2 D 3 was purchased from Santa Cruz Biotechnology Inc (Dallas, TX, USA). Tacalcitol and calcipotriol were purchased from TOCRIS Bioscience (Bristol, UK).
Cell culture. The human glioblastoma cell line T98G was cultured in Dulbecco's modified Eagle's medium (DMEM) with the addition of 10% foetal bovine serum and 1% antibiotic-antimycotic. The cells were grown in 5% CO 2 at +37°C in 100-mm tissue culture dishes. Prior to studies of viability and proliferation, the cells were seeded in 96-well plates.
MTT assay. The viability of T98G cells was measured by a colourimetric assay using MTT reduction. MTT is reduced to waterinsoluble MTT formazan by mitochondrial dehydrogenases of living cells. Cells were cultured in 96-well plates at a density of 2000 cells/well. On the following day, cells were treated with ethanol vehicle (control group), 1a,25(OH) 2 D 3 , tacalcitol or calcipotriol at the indicated concentrations. The treatment was repeated at day 3 and 5 after the initial plating. After 6 days of treatment, cells were incubated for 1 hr with 1.8 mM of MTT, dissolved in phosphate-buffered saline until purple coloured precipitates were visible. The supernatants were removed, and the formazan precipitates were solubilized by the addition of 200 ll isopropanol containing 0.7% SDS. The absorbance was measured at 570 nm using a microplate reader (FLUOstar Omega; BMG Labtech, V€ armd€ o, Sweden). Results are expressed as percentage of the absorbance in controls.
Assay of proliferation by manual cell counting. The cells were counted manually using a haemocytometer. Briefly, cells were plated in 96-well plates with 2000 cells/well. The next day, cells were treated with ethanol vehicle (control group), 1a,25(OH) 2 D 3 , tacalcitol or calcipotriol at the indicated concentrations. The treatment was repeated at day 3 and 5 after the initial plating. After 6 days of treatment, the medium was removed from the cultures. The attached cells were then trypsinized for 5 min. with trypsin/EDTA at 37°C and resuspended in equal volumes of growth medium and trypan blue solution 1:1. Triplicate aliquots were applied to the haemocytometer for cell counting on three different fields under a light microscope and then averaged. The results are expressed as percentage of cell count in the vehicle-treated cells (control).
Cell migration. Cell migration was measured by wound-healing assay [24] . Briefly, T98G cells were seeded in 60-mm Petri dishes and cultured until confluence. Cells were pre-treated with 10 lM tacalcitol, calcipotriol or 1a,25(OH) 2 D 3 for 24 hr. On the following day, cells were scraped with a 100-ll micropipette tip, and the wound area was monitored at 0 and 17 hr. The uncovered wound area was measured and quantified at different intervals with ImageJ 1.37v (NIH, Bethesda, MD, USA).
Measurement of lactate dehydrogenase (LDH) release. Lactate dehydrogenase activity was determined in the medium using Cytotoxicity Detection Kit (Roche, Solna, Sweden). Dead cells or cells with disrupted plasma membranes show increased LDH enzyme activity in the culture supernatant, which correlates with the formation of formazan. Cells were cultured in 96-well plates at a density of 2000 cells/well. The next day, medium was changed to DMEM without phenol red, supplemented with 2% foetal bovine serum, and cell cultures were treated for 72-120 hr with ethanol vehicle (control group), 1a,25(OH) 2 D 3 , tacalcitol or calcipotriol at the indicated concentrations, without changing media. Analysis was carried out according to the manufacturer's recommendations, and the absorbance was measured at 450 nm using a microplate reader (FLUOstar 
Reverse transcription polymerase chain reaction (RT-PCR).
Reverse transcription polymerase chain reaction was used to measure the expression of vitamin D receptor (VDR) in human glioblastoma cell line T98G. RNA was isolated from T98G cells using the RNeasy Mini kit (Qiagen, Sollentuna, Sweden), reversed transcribed to cDNA by Reverse Transcription System (Promega) and amplified with the AmpliTaq Gold system (Applied Biosystems, Stockholm, Sweden) in accordance with the manufacturer's recommendations. Sequencespecific primers for human VDR were as follows: forward 5 0 -AGCAGCGCATCTTGCCATA-3 0 and reverse 5 0 -CAGCATGGAG AGCTGGGACA-3 0 . Human kidney was used as positive control.
Assay of 3 H-thymidine incorporation. Cell cultures were incubated with tacalcitol (0.1-10 lM) or vehicle for 48 hr. During the last 4 hr of incubation, 3 H-thymidine was added to a final concentration of 2 mCi/ml. Cell lysates were then analysed by scintillation counting as previously described [25] . Thymidine is incorporated into new strands of chromosomal DNA during mitotic cell division.
Statistical analysis. Statistical significance was determined by analysis of variance (one-way ANOVA) followed by Tukey's post hoc test. The software used was Minitab â release 16 (Minitab Ltd, Coventry, UK). p-values *<0.05 and **<0.001 were considered statistically significant.
Results

VDR expression in the T98G cell line.
Previous studies reported expression of VDR in T98G cells [21, 26] . To confirm that significant expression could be detected in our cell cultures, we carried out RT-PCR with human kidney as positive control. As expected, the T98G cells showed expression of VDR (data not shown). fig. 4) . Treating cells for a longer time period only resulted in a reduced luminescent signal compared to the vehicle-treated cells. The luminescence measured in this assay is dependent on number of cells, and therefore, the growth-inhibiting effects of the treatment over time lead to difficulty measuring the luminescence signal. However, induction of caspase activities should not need longer incubation times than 24 hr, as is also shown by the substantial effect of the positive control staurosporine. Treatment with vitamin D analogues for shorter time periods than 24 hr did not have any impact on caspase activity.
Inhibitory effects of 1a,25(OH) 2 D 3 , tacalcitol and calcipotriol on cellular migration. We also wanted to study whether the vitamin D analogues had any effect on cellular migration, which is an important process in glioma progression. Cell proliferation and migration use a large number of shared signalling pathways, for example the activation of the small GTPases of the Rho family or the ERK cascade [28] . We analysed the effects of 1a,25(OH) 2 D 3 , tacalcitol and calcipotriol on cellular migration, using the wound-healing assay. Before wound induction, T98G cells were pre-treated with 10 lM 1a,25(OH) 2 D 3 , tacalcitol or calcipotriol for 24 hr. All three compounds reduced the migration rate of T98G cells compared to vehicle-treated cells (control) (fig. 5 ). After 17 hr, the wound closure of control cells was about 60%, while treated cells had a wound closure of about 35-45%.
Analysis of 3 H-thymidine incorporation in tacalcitol-treated cells.
Our experiments suggested that the effects by the vitamin D analogues were most likely caused by growth suppression, and that induction of cell death might play a minor role. To more specifically study whether effects on the cell cycle were present, we analysed proliferation using incorporation, an assay that measures DNA synthesis during cell division. Radiolabelled thymidine is incorporated into new strands of DNA during mitosis. We chose to use tacalcitol for this experiment, as our other data had indicated that it is somewhat more potent than calcipotriol. Incubation of T98G cells for 48 hr with tacalcitol in a concentration of 10 lM showed significant suppression of proliferation using this methodology ( fig. 6 ).
Discussion
Previous studies have shown that active vitamin D metabolites can inhibit cell proliferation and/or cell survival in various tumour types from different tissues [29] . Studies on the effects of active vitamin D in different cancer cell lines indicate effects on proliferation in some cell types but not in others [30] . GBM is the most lethal type of primary tumours of the CNS, and there is currently no cure for GBM [31] . Vitamin D metabolites are reported to cross the blood-brain barrier from the circulation, and both neurons and glial cells express the VDR and the enzyme CYP27B1 (1a-hydroxylase), responsible for converting 25(OH)D 3 to the active hormonal form 1a,25 (OH) 2 D 3 [5, 32] . Vitamin D could therefore be a potential therapeutic agent for treatment of GBM. However, although clinical studies have reported that high doses of 1a,25(OH) 2 D 3 can be safely given to patients [33, 34] , it is well established that the hyperphysiological doses necessary for antitumour activity of this compound can cause the side effect of hypercalcaemia. This is the prime rationale for development of analogues. Two analogues of the active vitamin D hormone, tacalcitol and calcipotriol, have been found to be efficient in the treatment of psoriasis with very few systemic side effects [35] . They have also shown antitumour activity in vitro on breast and colon cancer cells [36, 37] . Thus, reported data suggest that vitamin D analogues might be efficient also in the treatment of brain tumours.
A possible role for vitamin D analogues in the treatment of glioblastoma is supported by some previous findings. For instance, the expression of VDR is up-regulated in glioma tissue, as well as in other cancer cell types [21] . In addition, expression of VDR is related to better survival of patients with glioma. In some studies, human or rat glioma cells were found to respond to active vitamin D [38] . However, in a subclone of the rat C6 glioma cell line, lacking VDR expression, active vitamin D had no effect [39] .
Our present study with the human glioblastoma cell line T98G, which is known to express VDR, shows that both tacalcitol and calcipotriol have a substantial effect on the cells in experiments using MTT assay. Effects were significant in concentrations as low as 1 nM (cf. fig. 1 ). Tacalcitol had the most potent effect in comparison with 1a,25(OH) 2 D 3 , while calcipotriol was less active than 1a,25(OH) 2 D 3 at the highest concentration. It is not possible to determine from this assay alone whether the effect on the cells is due to inhibition of proliferation or inhibition of cell survival. To obtain more information on the nature of the observed effect, we studied potential effects on apoptosis. For these experiments, we chose higher treatment concentrations to be able to observe a clear result. Although many scientific studies on cell cultures in vitro use relatively high concentrations, it may be noted that the physiological serum levels of 1a,25(OH) 2 D 3 are in the pM range. It is, however, difficult to know which concentration of a synthetic analogue that might be considered most relevant, as this will also depend on how safe a particular compound is to give to patients. Some previous studies have suggested that 1a,25(OH) 2 D 3 may induce apoptosis in certain cancer cell types [40, 41] . In this study, we measured the activity of the apoptotic markers caspase-3 and -7. Little or no effect was observed on caspase activity by either 1a,25(OH) 2 D 3 , tacalcitol or calcipotriol, whereas staurosporine, included as positive control, increased caspase activity 17 times. Potential cytotoxic effects were also studied with LDH assay. Comparatively minor effects on LDH release were observed, and only at the highest concentration (10 lM), with no significant difference between the three tested compounds.
Experiments where cells were counted manually suggested a significantly lower cell count in cultures treated with 1a,25 (OH) 2 D 3 , tacalcitol or calcipotriol. To further study the effect of tacalcitol on proliferation, we carried out experiments using 3 H-thymidine incorporation. This assay, wherein 3 H-thymidine is incorporated into new strands of chromosomal DNA, measures effects on cell division. Treatment with tacalcitol strongly suppressed thymidine incorporation indicating an inhibition of the cell cycle before the S-phase. Taken together, our results indicate that vitamin D analogues act mainly through inhibition of proliferation in T98G cells, although some effect on cell viability cannot be excluded.
Malignant gliomas are highly invasive, and the invasion of distant brain tissue involves multiple biological processes. Many patients with GBM that receive a surgical resection develop immediately a recurrent tumour from invasive cells adjacent to the resection [42] . In this study, 1a,25(OH) 2 compared to cells treated with vehicle. The strongest inhibition of migration was observed with 1a,25(OH) 2 D 3 , but both tacalcitol and calcipotriol significantly inhibited migration by about 50% compared to control.
A number of experimental vitamin D analogues have been synthesized and described in the literature [20, 42] . Potential problems in developing this type of compounds for clinical use include the risk of systemic side effects, particularly on calcium homoeostasis. Also the half-life is important for consistent effects. Further studies are needed to fully evaluate the potential for treatment of glioblastoma with the vitamin D analogues reported in the present study and elsewhere. In animal studies, tacalcitol has been reported to show a higher antitumour and lower calcaemic activity as well as lower toxicity than 1a,25(OH) 2 D 3 . It has also been shown that tacalcitol has a similar or higher affinity for VDR than 1a,25(OH) 2 D 3 [19] . We believe that vitamin D analogues are interesting candidates in the search for effective human glioblastoma treatment, most likely to be used together with other compounds as part of a combination of strategies. For vitamin D analogues to be effective, tumours should express VDR. Interestingly, calcipotriol is reported to enhance the anticancer effect of the chemotherapeutic agent gemcitabine in an animal model of pancreatic cancer [43] .
In summary, the current data provide evidence that the vitamin D analogues tacalcitol and calcipotriol strongly reduce proliferation and migration of human glioblastoma T98G cells, suggesting a potential role for this type of compounds in the treatment of brain cancer.
